Latest

Brexit and the UK Pharma Industry

Eleanor Biggs looks at the biggest uncertainties facing the pharma industry if the UK were to leave the EU.

2016 Brand of the Year: Cancer Standout Opdivo

Pharm Exec’s 10th annual Brand of the Year has raced into the lead position in the treatment-shifting immuno-oncology space.

What Does the Future Hold for the UK's Pharmaceutical Price Regulation Scheme?

NHS England head Simon Stevens believes the UK's PPRS needs significantly updating.

New & Noteworthy

NICE Lite?

Is a more "light-touch" appraisal process the key to getting the UK's NICE to do more with less? Leela Barham reports.

Steering the Change: GSK's Jack Bailey

Pharm Exec speaks with GlaxoSmithKline's US Pharmaceuticals head Jack Bailey.

Pharma’s Big Push for Value

A “how to” primer for life sciences companies on applying end-to-end evidence strategies in demonstrating product value.

Alphabet’s Health Care Laundry List

When an 800-pound gorilla stakes a claim in an industry sector, the incumbents sit up and take notice—particularly when the gorilla is the parent company of Google.

Europe: What Price Medicines? The Subject That Won't Go Away

The dilemma continues: Which medicines should Europe's health systems pay for – and how much should they pay?

Sales & Marketing

Facebook’s New Algorithm: Attention, Engagement and World Domination

Facebook is the number one social-media network for businesses. Peter Houston asks, How can pharma stay relevant in the feed?

Twitter at 10: Prodigy or Problem Child?

Twitter, recently turned ten years old, has earned a seat at the top table of digital media. But exactly where it sits for marketers remains somewhat uncertain, writes Peter Houston.

The Digital Marketing Platforms That Will Stick Around

Peter Houston looks at the social and digital channels that look likely to still be here by the end of the year.

Featured E-Books

 

Securing the Global Supply Chain: Strategies for Operational Excellence

Strategic management of the supply chain is vital to winning with customers. Cost and quality are important, but they are not the only things customers care about: New services, flexibility in  relationships, supply reliability, and creatively overcoming obstacles in delivery of products are also core values. Pharmaceutical product portfolios and customers are becoming more complex. To stay ahead, customer-focused supply-chain capabilities is becoming an increasingly crucial part of a company’s competitive advantage. Visit the resource center.

 

The Changing Contours of Drug Commercialization

"The Changing Contours of Drug Commercialization," a new e-book from the editors of Pharmaceutical Executive, sheds light on solutions and strategies uniquely within a manufacturer's own sphere of control that can help navigate the often unforgiving transition from registration to the real-world battle for clinical acceptance and market share. Visit the resource center.  

 

Patient-Centric Approach to Product Commercialization

The industry's much talked-about patient-centered approach requires more than lip-service and organizational redesigns. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments.

 

The Path To Market Access: Winning Strategies To Build Value With Payers

Success in today’s rapidly changing market access world depends on understanding your product’s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.

 

 

View all e-books

PEspeaks

Europe's "Radical" Regulators Drawn Further into Pricing Debate

Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision.

Pharm Exec's Anti-Brand of the Year

The industry has much to be optimistic about in 2016. But a look at the winner of our “Anti-Brand of the Year” clarifies how many outside the industry really see it.

Any Chance for "Cures" Legislation This Year?

Election-year activities may stall the passage of biomedical innovation bill in 2016.

Pharm Exec at the Vantage Point

The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting. William Looney reports.

Interviews

Steering the Change: GSK's Jack Bailey

Pharm Exec speaks with GlaxoSmithKline's US Pharmaceuticals head Jack Bailey.

HBA's Woman of the Year 2016

Pharm Exec profiles Roche’s Jennifer Cook, this year’s winner of the Healthcare Businesswomen’s Association (HBA) Woman of the Year award.

Information in Action: DIA's Barbara Lopez Kunz

William Looney speaks with DIA's Global Chief Executive to see how the organization is repositioning itself.

Deeper Than Skin: LEO Pharma's Dermatology Drive

LEO Pharma CEO Gitte Aabo talks to PE about issues pertinent to dermatology.

Meeting the Multi-Channel Marketing Challenge

Novartis's Panos Papakonstantinou says pharma still needs to perfect its approach to multi-channel marketing.

Trusting Value, Valuing Trust

Pharm Exec talks value-based healthcare with Professor Bengt Jönsson of the Stockholm School of Economics.

Regulatory

Europe's "Radical" Regulators Drawn Further into Pricing Debate

Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision.

NICE Lite?

Is a more "light-touch" appraisal process the key to getting the UK's NICE to do more with less? Leela Barham reports.

Brexit and the UK Pharma Industry

Eleanor Biggs looks at the biggest uncertainties facing the pharma industry if the UK were to leave the EU.

From the Editor

Pharm Exec at the Vantage Point

The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting. William Looney reports.

The Odd Couple

The challenges facing the ad industry and big Pharma are remarkably similar—a point driven home by four distinct themes discussed at this year's 4A's Transformation conference.

Data Disclosure: Sealing the Error Envelope

With the emerging industry commitment to publicly disclose research and clinical trial results, two pivotal issues come to mind, writes William Looney.

lorem ipsum